Opaleye Management Inc.
Reported holdings as of Q2 2026, from 31 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| LIQUIDIA CORPORATION | LQDA | $195.1M | 2,447,500 | +5.97pp | 19q | -3.8%-$7.8M | |
| ETON PHARMACEUTICALS INC | ETON | $103.5M | 2,860,000 | +0.08pp | 31q | HELD | |
| HARROW INC | HROW | $101.9M | 2,400,000 | -3.92pp | 25q | -15.3%-$18.4M | |
| DISC MEDICINE INC | IRON | $62.5M | 855,000 | +2.12pp | 6q | +103.1%+$31.7M | |
| UROGEN PHARMA LTD | URGN | $53.0M | 1,439,996 | +1.41pp | 3q | +0.7%+$367.9K | |
| APOGEE THERAPEUTICS INC | APGE | $51.8M | 390,000 | +0.36pp | 4q | HELD | |
| MEIRAGTX HLDGS PLC | MGTX | $48.0M | 3,550,000 | +1.92pp | 3q | +67.2%+$19.3M | |
| SOL-GEL TECHNOLOGIES LTD | SLGL | $37.1M | 500,000 | -1.86pp | 4q | HELD | |
| REZOLUTE INC | RZLT | $32.8M | 6,300,000 | +0.44pp | 8q | HELD | |
| TG THERAPEUTICS INC | TGTX | $29.4M | 535,000 | +0.32pp | 12q | HELD | |
| IMMIX BIOPHARMA INC | IMMX | $24.2M | 2,345,000 | - | new | NEW | |
| CRESCENT BIOPHARMA INC. | CBIO | $23.7M | 1,319,351 | -1.03pp | 3q | +0.5%+$121.2K | |
| STOKE THERAPEUTICS INC | STOK | $22.9M | 700,000 | -0.93pp | 7q | HELD | |
| ALPHA COGNITION INC | ACOG | $20.9M | 2,895,467 | +0.04pp | 4q | +13.0%+$2.4M | |
| EDGEWISE THERAPEUTICS INC | EWTX | $20.3M | 500,000 | -0.23pp | 18q | HELD | |
| REVOLUTION MEDICINES INC | RVMD | $18.7M | 100,000 | +0.42pp | 5q | HELD | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $18.0M | 745,000 | - | new | NEW | |
| ALUMIS INC | ALMS | $15.5M | 550,000 | -0.19pp | 5q | HELD | |
| CODEXIS INC | CDXS | $15.3M | 6,785,000 | -0.07pp | 31q | HELD | |
| REPLIMUNE GROUP INC | REPL | $15.3M | 1,384,993 | - | new | NEW | |
| XOMA ROYALTY CORPORATION | XOMA | $14.4M | 338,374 | +0.06pp | 31q | +12.8%+$1.6M | |
| MBX BIOSCIENCES INC | MBX | $14.4M | 260,000 | +0.28pp | 6q | HELD | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $13.6M | 122,500 | -3.42pp | 17q | HELD | |
| EDITAS MEDICINE INC | EDIT | $12.5M | 3,861,930 | +0.51pp | 2q | +100.4%+$6.3M | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $12.3M | 100,000 | -0.28pp | 11q | HELD | |
| CABALETTA BIO INC | CABA | $12.0M | 3,863,800 | +0.60pp | 4q | +180.0%+$7.7M | |
| Q32 BIO INC | QTTB | $11.9M | 931,000 | +0.01pp | 3q | -25.9%-$4.1M | |
| ANNEXON INC | ANNX | $9.8M | 1,714,451 | -0.81pp | 4q | -26.5%-$3.5M | |
| VERASTEM INC | VSTM | $6.9M | 1,800,000 | - | new | NEW | |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | $6.9M | 1,412,656 | +0.19pp | 8q | HELD | |
| RELMADA THERAPEUTICS INC | RLMD | $6.5M | 935,000 | -0.27pp | 3q | HELD | |
| OCULAR THERAPEUTIX INC | OCUL | $5.9M | 600,000 | -0.14pp | 30q | HELD | |
| TREVI THERAPEUTICS INC | TRVI | $5.8M | 310,000 | -0.02pp | 15q | -10.2%-$654.6K | |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | $5.3M | 700,000 | +0.42pp | 2q | +1213.8%+$4.9M | |
| LYELL IMMUNOPHARMA INC | LYEL | $4.8M | 344,025 | +0.23pp | 2q | +334.9%+$3.7M | |
| OPUS GENETICS INC | IRD | $4.6M | 1,125,000 | +0.12pp | 6q | HELD | |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | $4.4M | 334,437 | +0.27pp | 2q | +197.8%+$3.0M | |
| INTELLIA THERAPEUTICS INC | NTLA | $4.2M | 250,000 | -0.03pp | 2q | +2.0%+$84.6K | |
| VOYAGER THERAPEUTICS INC | VYGR | $4.1M | 1,185,000 | -0.21pp | 3q | +3.0%+$122.5K | |
| BIODESIX INC | BDSX | $4.1M | 180,000 | -0.09pp | 2q | -24.4%-$1.3M | |
| ROCKET PHARMACEUTICALS INC | RCKT | $3.4M | 1,000,000 | -0.14pp | 3q | +4.7%+$153.9K | |
| JADE BIOSCIENCES INC | JBIO | $3.2M | 145,000 | -0.50pp | 3q | -66.1%-$6.3M | |
| SANUWAVE HEALTH INC | SNWV | $3.1M | 306,140 | -1.96pp | 6q | -68.8%-$6.8M | |
| FORTRESS BIOTECH INC | FBIO | $2.7M | 890,000 | -0.14pp | 3q | -14.6%-$465.1K | |
| JOURNEY MED CORP | DERM | $2.5M | 350,000 | -0.37pp | 6q | -63.5%-$4.3M | |
| PHATHOM PHARMACEUTICALS INC | PHAT | $2.0M | 185,589 | - | new | NEW | |
| INHIBRX BIOSCIENCES INC | INBX | $1.9M | 20,291 | - | new | NEW | |
| ENANTA PHARMACEUTICALS INC | ENTA | $1.8M | 125,000 | -0.04pp | 3q | HELD | |
| HEMAB THERAPEUTICS HLDGS INC | $1.8M | 47,652 | - | new | NEW | ||
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | $1.3M | 65,000 | - | new | NEW | |
| CG ONCOLOGY INC | CGON | $1.3M | 17,789 | -0.73pp | 6q | -81.2%-$5.5M | |
| BIOHAVEN LTD | BHVN | $1.2M | 77,915 | - | new | NEW | |
| ATEA PHARMACEUTICALS INC | AVIR | $1.1M | 235,000 | -0.13pp | 3q | -27.2%-$407.3K | |
| PASITHEA THERAPEUTICS CORP | KTTA | $1.1M | 2,050,000 | - | new | NEW | |
| ADC THERAPEUTICS SA | ADCT | $749.0K | 700,000 | - | new | NEW | |
| OKYO PHARMA LTD | OKYO | $562.8K | 375,204 | - | new | NEW | |
| PALATIN TECHNOLOGIES INC | PTN | $221.2K | 20,500 | - | new | NEW | |
| ADAGIO MED HLDGS INC | ADGM | $13.4K | 18,444 | flat | 8q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $1.1B | 96.4% |
| Other sectors | $22.5M | 2.0% |
| Not classified | $17.4M | 1.6% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $1.1B | 58 | 13 | 14 | 12 | 9 | 64.8% | 45 |
| Q1 2026 | $759.2M | 54 | 10 | 16 | 11 | 10 | 61.5% | 45 |
| Q4 2025 | $757.9M | 54 | 21 | 14 | 7 | 10 | 65.5% | 103 |
| Q3 2025 | $707.3M | 43 | 11 | 9 | 11 | 9 | 73.0% | 45 |
| Q2 2025 | $494.1M | 41 | 5 | 14 | 12 | 9 | 73.5% | 46 |
| Q1 2025 | $449.2M | 45 | 15 | 8 | 13 | 9 | 73.9% | 45 |
| Q4 2024 | $571.4M | 39 | 6 | 13 | 11 | 11 | 76.2% | 45 |
| Q3 2024 | $599.6M | 44 | 6 | 10 | 18 | 13 | 72.6% | 45 |
| Q2 2024 | $437.7M | 51 | 10 | 14 | 16 | 11 | 59.0% | 45 |
| Q1 2024 | $458.9M | 52 | 14 | 16 | 15 | 8 | 57.0% | 59 |
| Q4 2023 | $376.1M | 46 | 13 | 11 | 14 | 7 | 62.6% | 45 |
| Q3 2023 | $307.4M | 40 | 8 | 12 | 13 | 15 | 67.0% | 46 |
| Q2 2023 | $418.1M | 47 | 11 | 13 | 15 | 5 | 66.5% | 45 |
| Q1 2023 | $333.9M | 41 | 7 | 16 | 9 | 6 | 61.8% | 45 |
| Q4 2022 | $287.6M | 40 | 11 | 10 | 18 | 13 | 61.8% | 41 |
| Q3 2022 | $242.1M | 42 | 6 | 19 | 10 | 11 | 67.9% | 45 |
| Q2 2022 | $221.9M | 47 | 11 | 12 | 17 | 9 | 58.8% | 46 |
| Q1 2022 | $322.0M | 45 | 9 | 12 | 13 | 3 | 58.8% | 46 |
| Q4 2021 | $471.5M | 39 | 6 | 11 | 10 | 15 | 58.8% | 45 |
| Q3 2021 | $535.4M | 48 | 10 | 12 | 13 | 10 | 59.1% | 47 |
| Q2 2021 | $602.1M | 48 | 5 | 16 | 14 | 15 | 57.8% | 47 |
| Q1 2021 | $680.8M | 58 | 15 | 14 | 12 | 16 | 54.4% | 48 |
| Q4 2020 | $765.6M | 59 | 14 | 17 | 9 | 10 | 55.6% | 43 |
| Q3 2020 | $511.3M | 55 | 20 | 11 | 12 | 13 | 48.8% | 47 |
| Q2 2020 | $495.1M | 48 | 19 | 12 | 8 | 15 | 52.3% | 45 |
| Q1 2020 | $377.4M | 44 | 12 | 10 | 12 | 15 | 60.0% | 45 |
| Q4 2019 | $509.7M | 47 | 7 | 28 | 7 | 9 | 42.9% | 45 |
| Q3 2019 | $276.5M | 49 | 17 | 8 | 14 | 11 | 42.6% | 45 |
| Q2 2019 | $328.1M | 43 | 10 | 14 | 12 | 20 | 48.5% | 45 |
| Q1 2019 | $361.1M | 53 | 20 | 17 | 12 | 14 | 42.5% | 45 |
| Q4 2018 | $268.0M | 47 | 0 | 0 | 0 | 0 | 57.1% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.